Pharma industry in fightback against off-label legalization push in EU
This article was originally published in Scrip
The R&D-based pharmaceutical industry is refusing to take lying down moves by Italy and other EU countries to legalize off-label prescribing for purely financial reasons. It believes such practices threaten the very basis of the European drug regulatory system.
You may also be interested in...
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.